OPRM1 and neoplasm: The effect was reproduced with the use of another MOR antagonist methylnaltrexone, which also does not cross the blood–brain barrier; however, another peripherally acting opioid antagonist, loperamide, demonstrated tumour-promoting properties in this study [67].